Stock Events

Stock Events

Search...

Agios Pharmaceuticals

$47.96

20

+$0+0% Today

Statistics

Day High

47.96

Day Low

46.46

52W High

47.71

52W Low

20.13

Volume

436

Avg. Volume

522

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

31OctExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.72

-1.63

-1.54

-1.45

Expected EPS

-1.710352

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0HB0.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bluebird bio focuses on gene therapies for severe genetic diseases and cancer, overlapping with Agios's focus on rare genetic disorders.

CRISPR Therapeutics

CRISPR Therapeutics is involved in gene editing, a technology that could compete with Agios's approach to treating genetic diseases.

Vertex Pharmaceuticals

Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the rare disease market space.

Gilead Sciences

Gilead Sciences has a broad portfolio including oncology, competing in the cancer treatment space where Agios is also active.

Amgen focuses on human therapeutics, including treatments for cancer and cardiovascular disease, areas Agios is exploring.

Biomarin Pharmaceutical

BioMarin Pharmaceutical specializes in enzyme replacement therapies for rare genetic disorders, directly competing with Agios's focus areas.

Sangamo Therapeutics

Sangamo Therapeutics works on genomic medicine, including gene therapy, competing in the genetic disease treatment area.

Novartis offers a wide range of healthcare solutions, including treatments for cancer and rare diseases, overlapping with Agios's market.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in RNAi therapeutics for rare genetic diseases, competing in the same niche as Agios.

Beam Therapeutics

Beam Therapeutics specializes in precision genetic medicines using base editing, a novel approach that competes with Agios's strategies.

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Show more...

CEO

Dr. Bruce D. Car DACVP, Ph.D.

Employees

390

Country

United States

ISIN

US00847X1046

Listings